期刊文献+

间充质干细胞在癌症治疗中的应用潜能 被引量:2

Application of potential of mesenchymal stem cell in the treatment of cancer
暂未订购
导出
摘要 干细胞在恶性肿瘤中的应用受到越来越多的研究与探讨。间充质干细胞具有天然免疫豁免特性、向肿瘤细胞迁移的能力、多系分化的潜能,使其成为抗肿瘤的一种生物制剂。在肿瘤生长微环境下,间充质干细胞具有双重作用:促肿瘤形成和抗肿瘤形成。哪种作用占优势,取决于间充质干细胞的类型及来源,肿瘤细胞的类型,干细胞与机体免疫细胞、癌细胞的相互作用等。间充质干细胞分泌的肿瘤坏死因子相关凋亡诱导配体具有促进肿瘤细胞凋亡的作用。脐带组织来源的间充质干细胞与癌细胞共培养,可促进干细胞表达该配体,具有抗肿瘤作用。对间充质干细胞的促肿瘤形成和抗肿瘤形成的特性进行综述。 Stem cell treatments are being increasingly explored for their possible potential to treat variouscancers. Mesenchymal stem cells are believed to possess anti-tumor potential and are preferred for theirproperties like immune privileged nature, ability to migrate to the site of tumor and capability for multilineagedifferentiation. This tumor tropism property of MSCs could be utilized to deliver anti-tumor biological agents tothe site of tumor. In a tumor micro-environment, MSCs are believed to play both, a pro-tumorigenic and an anti-tumorigenic role. However, this is dependent on a host of factors like, types of MSCs, its source, type of cancercell line under investigation, interactions between MSCs, host's immune cells and cancer cells. Among severalcytokines secreted by MSCs, TRAIL (Tumor necrosis factor related apoptosis inducing ligand) are reported to bepro-apoptotic for tumor cells. Umbilical cord tissue derived MSCs are believed to regulate TRAIL expressionin MSC-cancer cell co-culture system resulting in induction of apoptosis in cancer cells. We present a reviewconcerning on pro-tumorigenic and anti-tumorigenic properties of MSCs based on different studies reporting.
出处 《医学研究与教育》 CAS 2015年第5期93-97,共5页 Medical Research and Education
关键词 间充质干细胞 肿瘤 趋向性 抗癌 mesenchymal stem cells tumor tropism anti-cancer
  • 相关文献

参考文献5

二级参考文献132

  • 1武晓静,黄岚,周骐,宋耀明,李爱民,晋军.骨髓基质干细胞种植体外修复内皮及对血管平滑肌细胞增生的影响[J].中华老年心脑血管病杂志,2005,7(3):188-191. 被引量:14
  • 2陈晓春,单鸿伟,瞿海龙,葛均波,葛智平.骨髓间充质干细胞移植加重大鼠主动脉血管成形术后再狭窄程度[J].中华心血管病杂志,2007,35(9):802-806. 被引量:21
  • 3BELTRAMI A P, BARLUCCHI L, TORELLA D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration[J]. Cell, 2003, 114(6): 763-776.
  • 4BERGMANN O, BHARDWAJ R D, BERNARD S, et al. Evidence for cardiomyocyte renewal in humans[J]. Science, 2009, 324(5923): 98-102.
  • 5MENASCHE P, HAGEGE A A, SCORSIN M, et al. Myoblast transplantation for heart failure[J]. Lancet, 2001, 357(9252): 279- 280.
  • 6MENASCHP, ALFIERI O, JANSSENS S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation[J]. Circulation, 2008, 117(9): 1189-1200.
  • 7SCHACHINGER V, ERBS S, ELSASSER A, et al. Intracoronary bone marrow-derived progenitor cells in acute myoeardial infarction[J]. N Engl J Med, 2006, 355(12): 1210-1221.
  • 8IEEVANANTHAM V, BUTLER M, SAAD A, et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis[J]. Circulation, 2012, 126(5): 551- 568.
  • 9HARE J M, TRAVERSE J H, HENRY T D, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells(prochymal)after acute myocardial infarction[J]. J Am Coil Cardiol, 2009, 54(24): 2277-2286.
  • 10HARE J M, FISHMAN J E, GERSTENBLITH G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial[J]. JAMA, 2012, 308(22): 2369-2379.

共引文献28

同被引文献5

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部